Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0194-0499 + semaglutide in NASH
NCT05016882Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2021
- Primary completion
- Dec 2024
- Modality
- Hormonal Peptides
- Countries
- 24
01
Overview
A Phase 2 trial of nn9500 in Nonalcoholic steatohepatitis (NASH), sponsored by Novo Nordisk. Started Aug 2021; status: completed.
02
Drugs
nn9500
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05016882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05016882.